FY22 Q3 Updates
|
Study |
Sponosor |
Recipient(s) |
|---|---|---|
|
Secondary Data Analysis for Neonates with Retinal OCT Imaging - 1R21-EY034138-01 |
National Institutes of Health |
Cynthia Toth, MD |
|
Blink, Lacrimation, and Nociception: Precision Mapping and Integrated Atlas Generation of Corneal Trigeminal Afferents - 1U01-EY034687-01 |
National Institutes of Health |
Daniel Saban, PhD (contact/lead), Victor Perez, MD, Sina Farsiu, PhD (Duke), Mihaela Gadjeva, PhD (UCLA) |
|
Elucidating perifoveal vascular development in infants - 1R01-EY034134-01 |
National Institutes of Health |
Xi Chen, MD, PhD |
|
Defining the Immune Cell Roles in Meibomian Gland Dysfunction in the Context of Ocular Surface Immune Diseases - 2R01-EY021798-11 |
National Institutes of Health |
Daniel Saban, PhD |
|
Autophagy and Retinal Ganglion Cell Death in Glaucoma - 1R01-EY033600-01 |
National Institutes of Health |
Paloma Liton, PhD |
|
Study |
Sponsor |
Recipient |
|---|---|---|
|
Autophagy regulates endothelial nitric oxide (NO) synthase/NO in Schlemm's canal cells in response to shear stress |
Brightfocus Foundation |
Myoungsup Sim, PhD |
|
Clinical Research Fellowship |
Baton Rouge Area Foundation | Ramiro Maldonado, MD |
| Rate of Progression of PCDH15 Related Retinal Degeneration (RUSH1F) | Foundation Fighting Blindness Inc. | Ramiro Maldonado, MD |
| Activation of Cellular Proteostasis as an Approach to Treat Inherited Retinal Degenerations | Foundation Fighting Blindness Inc. | Vadim Arshavsky, PhD |
|
Study |
Sponsor |
Recipient |
|---|---|---|
|
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
Alexion Pharmaceuticals, Inc |
Madja Hadziahmetovic, MD |
|
Animal models of Glaucoma and Eye Disease |
Aerie Pharmaceuticals |
Pratap Challa, MD |
|
The Swine model of VEGF-induced vascular leakage and interventions thereof |
Aerie Pharmaceuticals |
Pratap Challa, MD |
|
A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, A Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED) |
Viridian Therapeutics |
Chantal Boisvert, MD, OD |
|
A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) |
Ocular Therapeutix |
Leon Herndon, MD |
|
A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract |
Ocular Therapeutix |
Laura Enyedi, MD |
|
A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery |
Eyepoint Pharmaceuticals |
Sanjay Asrani, MD |